Aclaris Therapeutics
Wayne, Pennsylvania, United States · Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
Key facts
- Headquarters
- Wayne, Pennsylvania, United States
- Employees
- 56
- Industries
- Healthcare
- Status
- Public (ACRS)
- Website
- aclaristx.com
- Company page
Recent activity at Aclaris Therapeutics
- : SEC 8-K (8.01): On October 27, 2026, Aclaris Therapeutics, Inc. issued a press release announcing primary analysis results from the Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 for atopic dermatitis and asthma. The results were presented alongside the announcement of a forthcoming webcast and conference call. The statement also disclosed that Aclaris's preliminary estimate for cash, cash equivalents, and marketable securities stood at approximately $204.6 million as of September 30, 2026, emphasizing that this figure may differ following comprehensive accounting procedures. This public disclosure is significant for stakeholders assessing the company's financial health and ongoing clinical trials, impacting future investment and strategic decisions.
- : SEC 8-K (1.01): On October 27, 2026, Aclaris Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co. to issue and sell 7,785,714 shares of common stock and pre-funded warrants for an estimated $46.7 million in net proceeds. The shares are priced at $3.50 each, while the warrants are priced at $3.49999 each. The closing of the offering is expected to occur on October 28, 2026, subject to customary closing conditions. The agreement includes typical representations and warranties, along with indemnification obligations for liabilities under the Securities Act.
- : Aclaris Therapeutics Raises $46.7 Million in Underwritten Offering
- : SEC 8-K (1.01): On August 6, 2026, Aclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. This agreement allows the Company to offer and sell shares of common stock at its discretion, with a total potential offering size of up to $100.0 million. Under this agreement, the Company will pay a commission of 3.0% on gross sales proceeds to the sales agents. The transaction is structured as an 'at the market offering' in compliance with Rule 415 of the Securities Act, and customary representations and warranties have been provided. The agreement signifies a strategic move by the Company to enhance its capital-raising capabilities while retaining flexibility over the timing and amount of stock sales.
- : SEC 8-K (8.01): On April 28, 2026, Aclaris Therapeutics, Inc. issued a press release announcing the results of the ATI-052 and ATI-2138 clinical trials. This release highlights significant findings from these trials which may influence upcoming strategic decisions and stakeholder perceptions. The press release, along with a company presentation dated the same day, is included as an exhibit in this filing. The announcement is a critical update for investors and could have implications for future product development and regulatory strategies.
- : SEC 8-K (7.01): On March 10, 2026, Aclaris Therapeutics, Inc. disclosed the sale of 5.7 million shares of its common stock, generating aggregate gross proceeds of $20.0 million. This transaction was conducted under the company's amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., dated February 27, 2025. The shares were acquired by Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP. This event highlights the company's capital-raising efforts and financial partnerships, contributing to its strategic positioning in the market.
- : SEC 8-K (7.01): From March 2, 2026 through March 9, 2026, Aclaris Therapeutics, Inc. sold 12.7 million shares of its common stock, generating aggregate gross proceeds of $39.8 million. This transaction was conducted under the Company's amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., dated February 27, 2025. Institutional investors, including Deep Track Capital, participated in the purchase of these shares. The event's date indicates it recently occurred, highlighting the Company's capital raising efforts and investor engagement.
- : SEC 8-K (7.01): On January 12, 2026, Aclaris Therapeutics, Inc. announced an update to its corporate overview presentation, indicating ongoing efforts to provide shareholders with the latest company information. This update, which is accessible on the company's website, is intended to enhance transparency and keep investors informed about the company's strategic vision and initiatives. The filing includes Exhibit 99.1, which contains the updated presentation, reflecting the company's progress and future plans. As a Regulation FD disclosure, this information serves to ensure that all shareholders receive material updates simultaneously, thereby promoting fair disclosure.
- : SEC 8-K (7.01): On January 6, 2026, Aclaris Therapeutics, Inc. disclosed interim results from its first-in-human Phase 1a single and multiple ascending dose trial of the anti-TSLP/IL-4Rα bispecific antibody, ATI-052. This filing includes an announcement of a forthcoming webcast and conference call to discuss these interim results. The specifics of the trial results indicate a significant advancement in their drug development process, showcasing the efficacy and safety of ATI-052. Accompanying documents, including a press release and presentation slides, are provided as exhibits.
- : SEC 8-K (8.01): The 8-K filing reports interim results from a Phase 1a SAD/MAD trial of ATI-052, focusing on its safety, tolerability, and pharmacokinetics in healthy adults. The trial included various doses, with results indicating that ATI-052 was well-tolerated with a favorable safety profile, and demonstrated significant pharmacodynamic effects, including robust target engagement. Importantly, no serious adverse events were reported, and dosing showed potential for up to three-month intervals. The company plans to proceed with a Phase 1b proof-of-concept trial in atopic dermatitis imminently and a similar trial in asthma in Q1 2026, with expected top-line data later that year. The announcement reinforces the viability and strategic importance of ATI-052 in treating atopic conditions.
Aclaris Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Post-IPO Equity | $46.7M |
| Dec 2024 | Venture | $80.0M |
| Apr 2020 | Venture | $11.0M |
| Aug 2017 | Venture | $10.0M |
| Jun 2016 | Venture | $20.0M |
Leadership
- Neal Walker, Executive Officer, Director
- Christopher Molineaux, Director
- Anand Mehra, Director
- William Humphries, Director
- Andrew Powell, Director
- Andrew Schiff, Director
- Bryan Reasons, Director
- Maxine Gowen, Director
- Vincent Milano, Director
Verified email and direct lines for Aclaris Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Aclaris Therapeutics files 4 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Aclaris Therapeutics in the news
- Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - GlobeNewswire (Apr 27, 2026)
- Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - GlobeNewswire (May 07, 2026)
- Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire (Oct 27, 2026)
- Aclaris Therapeutics Receives Fast Track Designation for - GlobeNewswire (Aug 06, 2026)
- Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire (Sep 03, 2026)
- Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update - GlobeNewswire (Aug 06, 2026)
- Aclaris Therapeutics Announces Positive Phase 1b - GlobeNewswire (Oct 27, 2026)
- Aclaris Therapeutics Announces Poster on Results from Phase - GlobeNewswire (Mar 20, 2026)
Companies similar to Aclaris Therapeutics
- Enlaza Therapeutics · Healthcare
- Notable Systems · Healthcare
- Cognito Therapeutics · Healthcare
- Lungpacer Medical · Healthcare
- Omniscient Neurotechnology · Healthcare
About Aclaris Therapeutics: questions and answers
What does Aclaris Therapeutics do?
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
Where is Aclaris Therapeutics headquartered?
Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, United States.
How many employees does Aclaris Therapeutics have?
Aclaris Therapeutics has about 56 employees.
Has Aclaris Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Aclaris Therapeutics. The most recent, Post-IPO Equity of $46.7M, was in Oct 2026.
What is the latest news on Aclaris Therapeutics?
On Oct 27, 2026, SEC 8-K (8.01): On October 27, 2026, Aclaris Therapeutics, Inc. issued a press release announcing primary analysis results from the Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 for atopic dermatitis and asthma. The results were presented alongside the announce
Is Aclaris Therapeutics a public company?
Yes. Aclaris Therapeutics is publicly traded under the ticker ACRS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy